225 related articles for article (PubMed ID: 33509236)
1. High expression of ABCG2 is associated with chemotherapy resistance of osteosarcoma.
Shu H; Yuan B; Huang Y; Wang L; He B; Sun Q; Sun L
J Orthop Surg Res; 2021 Jan; 16(1):85. PubMed ID: 33509236
[TBL] [Abstract][Full Text] [Related]
2. LncRNA Sox2OT-V7 promotes doxorubicin-induced autophagy and chemoresistance in osteosarcoma via tumor-suppressive miR-142/miR-22.
Zhu K; Yuan Y; Wen J; Chen D; Zhu W; Ouyang Z; Wang W
Aging (Albany NY); 2020 Apr; 12(8):6644-6666. PubMed ID: 32302291
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic virotherapy reverses chemoresistance in osteosarcoma by suppressing MDR1 expression.
Sugiu K; Tazawa H; Hasei J; Yamakawa Y; Omori T; Komatsubara T; Mochizuki Y; Kondo H; Osaki S; Fujiwara T; Yoshida A; Kunisada T; Ueda K; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Chemother Pharmacol; 2021 Sep; 88(3):513-524. PubMed ID: 34114067
[TBL] [Abstract][Full Text] [Related]
4. A Combined Bioinformatic and Nanoparticle-Based Study Reveal the Role of ABCG2 in the Drug Resistant Breast Cancer.
Huo Q; Yuan J; Zhu T; Li Z; Xie N
Recent Pat Anticancer Drug Discov; 2021; 16(3):393-406. PubMed ID: 33602075
[TBL] [Abstract][Full Text] [Related]
5. Long non-coding RNA CTA sensitizes osteosarcoma cells to doxorubicin through inhibition of autophagy.
Wang Z; Liu Z; Wu S
Oncotarget; 2017 May; 8(19):31465-31477. PubMed ID: 28415557
[TBL] [Abstract][Full Text] [Related]
6. circ_0002060 Enhances Doxorubicin Resistance in Osteosarcoma by Regulating the miR-198/ABCB1 Axis.
Ji Y; Liu J; Zhu W; Ji J
Cancer Biother Radiopharm; 2023 Nov; 38(9):585-595. PubMed ID: 33351694
[No Abstract] [Full Text] [Related]
7. Mitochondria-Targeted Doxorubicin: A New Therapeutic Strategy against Doxorubicin-Resistant Osteosarcoma.
Buondonno I; Gazzano E; Jean SR; Audrito V; Kopecka J; Fanelli M; Salaroglio IC; Costamagna C; Roato I; Mungo E; Hattinger CM; Deaglio S; Kelley SO; Serra M; Riganti C
Mol Cancer Ther; 2016 Nov; 15(11):2640-2652. PubMed ID: 27466354
[TBL] [Abstract][Full Text] [Related]
8. SIAH1/ZEB1/IL-6 axis is involved in doxorubicin (Dox) resistance of osteosarcoma cells.
Han X; Liu F; Zhang C; Ren Z; Li L; Wang G
Biol Chem; 2019 Mar; 400(4):545-553. PubMed ID: 30265649
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone modulates doxorubicin resistance in a in vivo model of drug resistant osteosarcoma xenograft.
Natarajan A; Ramachandran B; Gopisetty G; Jayavelu S; Sundersingh S; Rajkumar T
Naunyn Schmiedebergs Arch Pharmacol; 2021 Feb; 394(2):361-371. PubMed ID: 33015747
[TBL] [Abstract][Full Text] [Related]
10. GPER mediates decreased chemosensitivity via regulation of ABCG2 expression and localization in tamoxifen-resistant breast cancer cells.
Yu T; Cheng H; Ding Z; Wang Z; Zhou L; Zhao P; Tan S; Xu X; Huang X; Liu M; Peng M; Qiu YA
Mol Cell Endocrinol; 2020 Apr; 506():110762. PubMed ID: 32087276
[TBL] [Abstract][Full Text] [Related]
11. ABCG2 aptamer selectively delivers doxorubicin to drug-resistant breast cancer cells.
Hashemitabar S; Yazdian-Robati R; Hashemi M; Ramezani M; Abnous K; Kalalinia F
J Biosci; 2019 Jun; 44(2):. PubMed ID: 31180052
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase 6 regulated expression of IL-8 is involved in the doxorubicin (Dox) resistance of osteosarcoma cells via modulating ABCB1 transcription.
Cheng M; Cai W; Huang W; Chen Y; Wu Z; Luo P; Yan W
Eur J Pharmacol; 2018 Dec; 840():1-8. PubMed ID: 30273544
[TBL] [Abstract][Full Text] [Related]
13. Small Nucleolar RNAs Determine Resistance to Doxorubicin in Human Osteosarcoma.
Godel M; Morena D; Ananthanarayanan P; Buondonno I; Ferrero G; Hattinger CM; Di Nicolantonio F; Serra M; Taulli R; Cordero F; Riganti C; Kopecka J
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32599901
[TBL] [Abstract][Full Text] [Related]
14. LncRNA NORAD targets miR-410-3p to regulate drug resistance sensitivity of osteosarcoma.
Xie X; Liu W; Duan Z; Li X; Zhang L; Yang G
Cell Mol Biol (Noisy-le-grand); 2020 Jun; 66(3):143-148. PubMed ID: 32538761
[TBL] [Abstract][Full Text] [Related]
15. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model.
Tiash S; Chowdhury EH
J Drug Target; 2019 Mar; 27(3):325-337. PubMed ID: 30221549
[TBL] [Abstract][Full Text] [Related]
16. A Novel Synthetic Dihydroindeno[1,2-b] Indole Derivative (LS-2-3j) Reverses ABCB1- and ABCG2-Mediated Multidrug Resistance in Cancer Cells.
Guo C; Liu F; Qi J; Ma J; Lin S; Zhang C; Zhang Q; Zhang H; Lu R; Li X
Molecules; 2018 Dec; 23(12):. PubMed ID: 30544754
[TBL] [Abstract][Full Text] [Related]
17. Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma.
Sukowati CH; Rosso N; Pascut D; Anfuso B; Torre G; Francalanci P; Crocè LS; Tiribelli C
BMC Gastroenterol; 2012 Nov; 12():160. PubMed ID: 23153066
[TBL] [Abstract][Full Text] [Related]
18. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
19. USP10 suppresses ABCG2-induced malignant characteristics of doxorubicin-resistant thyroid cancer by inhibiting PI3K/AKT pathway.
Sun J; Xiang Q; Ding D; Yan N
J Bioenerg Biomembr; 2023 Dec; 55(6):457-466. PubMed ID: 37919637
[TBL] [Abstract][Full Text] [Related]
20. CCN2 promotes drug resistance in osteosarcoma by enhancing ABCG2 expression.
Tsai HC; Chang AC; Tsai CH; Huang YL; Gan L; Chen CK; Liu SC; Huang TY; Fong YC; Tang CH
J Cell Physiol; 2019 Jun; 234(6):9297-9307. PubMed ID: 30317661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
